It has a known [[adverse drug reaction|side effect]], [[retroperitoneal fibrosis]]/retropulmonary fibrosis,<ref>[http://www.emedicine.com/radio/topic605.htm emedicine.com (2002)]</ref> which is severe, although uncommon. This side effect has been estimated to occur in 1/5000 patients <ref>{{cite journal|last1=Silberstein|first1=SD|date=1998 Sep|title=Methysergide|url=https://www.ncbi.nlm.nih.gov/pubmed/9793694|journal=Cephalalgia|volume=18|issue=7|pages=421-35.|doi=10.1111/j.1468-2982.1998.1807421.x|pmid=9793694|accessdate=6 September 2017}}</ref>. Though no meta-analysis been performed to date to confirm or deny this date, the statistics used to support have been repeated in literature as fact over. 

 


 
In order to avoid the occurrence of retroperitoneal fibrosis/retropulmonary fibrosis, it is advised  

 


 
In addition, there is an increased risk of left-sided [[cardiac valve dysfunction]].<ref name=Tam/><ref name=mayo>[http://pph.poweradvocates.com/fen_phen_study_mayo.html 1997 Mayo Clinic study linking heart disease to Fen Phen] Valvular heart disease associated with fenfluramine-phentermine  {{webarchive |url=https://web.archive.org/web/20071207200720/http://pph.poweradvocates.com/fen_phen_study_mayo.html |date=December 7, 2007 }}</ref>

 

